Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 75/100

SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023

Key Takeaway: SI-BONE, Inc. announced its participation in the Morgan Stanley 21st Annual Global Healthcare Conference scheduled for September 12, 2023. During the event, management will host a fireside chat at 9:30 a.m. ET. The conference presents an opportunity for investors to gain insights into the company’s advancements in musculoskeletal disorders treatment. SI-BONE has established itself as a leader in minimally invasive surgical technologies with extensive clinical backing.

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE will be presenting at a major global healthcare conference.
  • The company has a strong track record with over 85,000 sacropelvic procedures.
  • SI-BONE has substantial clinical evidence supporting its technologies.

Full Press Release Details

SANTA CLARA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Tuesday, September 12, 2023, at 9:30 a.m. Eastern Time / 6:30 a.m. Pacific Time.
Investors interested in listening to the conference call may do so by registering at this link: https://cc.webcasts.com/morg007/091123a_js/?entity=158_QRFN47W. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,000 surgeons in performing a total of over 85,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 120 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
Sr. Director, FP&A and Investor Relations

Frequently Asked Questions

What is SI-BONE, Inc. known for?

SI-BONE focuses on technologies for treating sacropelvic musculoskeletal disorders.

When is SI-BONE's fireside chat at the conference?

The fireside chat is on September 12, 2023, at 9:30 a.m. ET.

How can I listen to the SI-BONE conference call?

Investors can register for the call via a provided link or visit the company’s website.

What evidence supports SI-BONE's technologies?

SI-BONE's technologies are backed by clinical evidence, including two trials and over 120 publications.

Where can I find more information about SI-BONE?

More information is available on SI-BONE's website at www.si-bone.com.

Last updated: Aug 29, 2023